ロード中...
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramuciru...
保存先:
| 出版年: | Liver Int |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496898/ https://ncbi.nlm.nih.gov/pubmed/32432830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14533 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|